Cargando…

Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients

The mineralocorticoid receptor antagonist spironolactone has been shown to improve cardiac function and reverse left ventricular hypertrophy in heart failure patients, but there are no consistent findings on the efficacy and safety in hemodialysis patients. Abnormal aldosterone secretion plays a cri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Zuoya, Chen, Zhiyuan, Liu, Ruihong, Lu, Gang, Li, Zhuo, Sun, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882618/ https://www.ncbi.nlm.nih.gov/pubmed/36712946 http://dx.doi.org/10.2147/DDDT.S393480

Ejemplares similares

Regression of Left Ventricular Hypertrophy in Patients Combined with Peritoneal Dialysis and Hemodialysis
por: Luyan, Gao, et al.
Publicado: (2022)

Electrocardiographic Left Ventricular Hypertrophy and Outcome in Hemodialysis Patients
por: Kim, Seung Jun, et al.
Publicado: (2012)

The role of mitofilin in left ventricular hypertrophy in hemodialysis patients
por: Wu, Qi-Shun, et al.
Publicado: (2018)

Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis
por: Al-Hilali, N., et al.
Publicado: (2009)

Cardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients
por: Koycheva, Reneta Yovcheva, et al.
Publicado: (2016)

Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts
por: Hwang, Hyeon Seok, et al.
Publicado: (2018)

Carotid intima-media thickness and left ventricular hypertrophy in hemodialysis patients
por: Rafieian-Kopaei, Mahmoud, et al.
Publicado: (2013)

QTc and QTcd Measurements and Their Relationships with Left Ventricular Hypertrophy in Hemodialysis Patients
por: Yasri, Sora, et al.
Publicado: (2018)

Uric acid and left ventricular hypertrophy: another relationship in hemodialysis patients
por: Selim, Gjulsen, et al.
Publicado: (2019)

Electrocardiographic parameters of left ventricular hypertrophy and prediction of mortality in hemodialysis patients
por: Braunisch, Matthias C., et al.
Publicado: (2021)

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

Close association of arterial plaques with left ventricular hypertrophy and ejection fraction in hemodialysis patients
por: Mowlaie, Morteza, et al.
Publicado: (2014)

Reproducibility and Reliability Of QTc and QTcd Measurements and Their Relationships with Left Ventricular Hypertrophy in Hemodialysis Patients
por: Alonso, Maria Angélica Gonçalves, et al.
Publicado: (2017)

Vitamin D receptor gene polymorphism predicts left ventricular hypertrophy in maintenance hemodialysis
por: Liu, Bingman, et al.
Publicado: (2022)

Echocardiographic left ventricular hypertrophy and geometry in Chinese chronic hemodialysis patients: the prevalence and determinants
por: Zhao, Xinju, et al.
Publicado: (2022)

Spironolactone and Cardiac Arrhythmias in Hemodialysis Patients: Helpful or Harmful?
por: Pun, Patrick H.
Publicado: (2023)

Moexipril and left ventricular hypertrophy
por: Chrysant, George S, et al.
Publicado: (2007)

Left ventricular hypertrophy: is it really?
por: Mikolich, J Ronald, et al.
Publicado: (2013)

Protein Carbonyl Content Is a Predictive Biomarker of Eccentric Left Ventricular Hypertrophy in Hemodialysis Patients
por: Dimitrijevic, Zorica M., et al.
Publicado: (2019)

Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
por: Sacharczuk, Wioletta, et al.
Publicado: (2023)

Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis
por: Zeng, Qing, et al.
Publicado: (2019)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Myocardial Energetics in Left Ventricular Hypertrophy
por: Jameel, Mohammad N, et al.
Publicado: (2009)

Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis
por: Khangura, Jaspreet, et al.
Publicado: (2010)

The Association of Long-Functioning Hemodialysis Vascular Access with Prevalence of Left Ventricular Hypertrophy in Kidney Transplant Recipients
por: Kolonko, Aureliusz, et al.
Publicado: (2014)

Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers
por: Bacharova, Ljuba, et al.
Publicado: (2023)

Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat
por: Leader, Catherine J., et al.
Publicado: (2020)

Combined superposition effect of hypertension and dyslipidemia on left ventricular hypertrophy
por: Zhang, Xueyao, et al.
Publicado: (2022)

Relationship among Left Ventricular Hypertrophy, Cardiovascular Events, and Preferred Blood Pressure Measurement Timing in Hemodialysis Patients
por: Io, Hiroaki, et al.
Publicado: (2020)

Impact of Overhydration on Left Ventricular Hypertrophy in Patients With Chronic Kidney Disease
por: Sun, Lianqin, et al.
Publicado: (2022)

Electrocardiographic Criteria for Left Ventricular Hypertrophy in Children
por: Rijnbeek, Peter R., et al.
Publicado: (2008)

The Role of ECG in the Diagnosis of Left Ventricular Hypertrophy
por: Bacharova, Ljuba, et al.
Publicado: (2014)

Left ventricular hypertrophy, inflammation, and insulin resistance
por: Öncel, Can Ramazan
Publicado: (2016)

Crim1 suppresses left ventricular hypertrophy
por: Yang, Long, et al.
Publicado: (2019)

Left ventricular apical hypertrophy (Yamaguchi disease)
por: Al Lawati, Hatim, et al.
Publicado: (2021)

Antifailure Therapy Including Spironolactone Improves Left Ventricular Energy Supply‐Demand Relations in Nonischemic Dilated Cardiomyopathy
por: Bell, Susan P., et al.
Publicado: (2014)

Frequency of Left Ventricular Hypertrophy Among Patients on Maintenance Hemodialysis by Voltage Criteria and Its Relationship with Biophysical-Chemical Parameters
por: Zanib, Alvina, et al.
Publicado: (2020)

Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial
por: Eklund, Michael, et al.
Publicado: (2022)

Correlation research between osteoporosis and left ventricular hypertrophy in older men
por: Huang, Chenshu, et al.
Publicado: (2016)

Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy
por: Han, Jae Yong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_13o0oqhc56c4pd3tdp8rv3mbi8